Colossal Biosciences Stock

colossal.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $228.04MM

Colossal Biosciences is a biotechnology company with the mission to bring back into existence past animal species currently extinct. The company employs teams of researchers to uncover methods of rebuilding DNA systems using CRISPR and genetic engineering to reawaken prehistoric life and biology.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Colossal Biosciences, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation
Private Market Pricing DetailsValuation & Financings

Colossal Biosciences Stock Price

Experience transparency. With Forge Price, our proprietary pricing model, investors and shareholders can access daily pricing data on private companies to better inform their buy and sell indications of interest.

Forge Price 1
Price not yet available
Last Closed Trade 2
Price per share
$xx.xx
Date
xx/xx/xx
90-Day VWAP 3
Price per share
$xx.xx
v Last Primary PPS
xxxxxx

Enterprise Value

Powered by Forge Data

Access Colossal Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Animation displayed is not current and securities are shown for illustrative purposes only.

Colossal Biosciences investors also invested in these private companies

Leadership & Board

Leadership

Adam Milne
Chief Operating Officer
Brian Beard, J.D.
Chief Legal Officer
Sam Singer, CFA
Chief Financial Officer
Sarah Grant
Chief of Staff
Peter Phillips
Chief Business Officer
Andrew Busey
Chief Product Officer

Board

Alexander Titus
Independent Advisor

Colossal Biosciences stock FAQs

plusminus

Can you buy Colossal Biosciences stock?

As Colossal Biosciences is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Colossal Biosciences, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Colossal Biosciences stock?

To invest in a private company like Colossal Biosciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Colossal Biosciences stock?

Yes, you may sell the Colossal Biosciences stock you currently own. Forge can help you facilitates the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Colossal Biosciences stock?

If you hold private company shares of Colossal Biosciences – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Colossal Biosciences on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Colossal Biosciences a public company?

No, Colossal Biosciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is stock price?

Colossal Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Colossal Biosciences private market stock price with Forge Data.
plusminus

What is stock ticker symbol?

Colossal Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Colossal Biosciences’ news and media highlights

As more species are pushed to the brink of extinction, conservationists are responding to our biodiversity crisis in new and sometimes controversial ways. One such novel approach could be described as the mammoth in the room: “de-extinction” technology that has the potential to protect and restore species on the brink of extinction and, more provocatively, those that disappeared from the planet long ago. We can avoid such innovation and the controversy that comes with it. But the reality is that many milestone moments in conservation have been contentious.
Inside the National Black-Footed Ferret Conservation Center, in Carr, Colorado, Dr. Della Garelle, a veterinarian with the U.S. Fish and Wildlife Service, is leading the effort to bring one of America's most endangered species back from the brink of extinction. "Sunday Morning" was invited to witness Garelle's physical exams of the ferrets ahead of breeding season. "We gotta check out the goods because, well, it's a breeding program, right? So, we can't be shy," she said. It was only a few decades ago that reproduction wasn't even thought possible; the species was believed to be extinct, due to habitat loss and disease. But in 1981 the federal government tracked down the only known colony, and started this breeding program, with just seven ferrets.
A biotechnology startup that promises to resurrect woolly mammoths is now the first “de-extinction unicorn,” with a valuation said to be over a $1 billion before bringing back a single lost species. Colossal Biosciences, the Dallas-based startup, is making public a new round of investment this week that will help fund its effort to bring back perhaps the most famously extinct animal of them all: the dodo. Reintroducing mammoths to Alaska or dodos to Mauritius sounds unrealistic, even silly, and has drawn skepticism from paleo-geneticists and other experts who worry that the effects of de-extinction would be unpredictable. Yet Colossal has continued to draw support from investors, including celebrities, and on Tuesday announced another $150 million for a total of $225 million since 2021.
Colossal Biosciences, the world’s first de-extinction company, has today announced an oversubscribed $150M Series B financing led by United States Innovative Technology Fund (“USIT”), with participation from Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, and Jazz Ventures, among others. Since launching in September 2021, Colossal has raised $225M in total funding. Colossal will leverage this latest infusion of capital to continue to advance genetic engineering and pioneer new revolutionary software, wetware and hardware solutions, all of which have applications to de-extinction, conservation and human healthcare.
Updated on: Sep 8, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price™ may rely on a very limited number of inputs in its calculation. Forge Price™ is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price™, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price™. Forge Price™ is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price™ is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price™ for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

3. 90-Day volume-weighted average price (VWAP) is calculated from transactions on Forge Markets in the preceding 90 days. The comparison (in green or red) demonstrates the difference between 90-Day VWAP and the company's most recent funding round share price estimate. The price shown for 90-Day VWAP is calculated from the price and volume for all transactions, buys or sells. VWAP does not include pricing information from other sources and may be materially different from transaction prices for the same company outside of Forge Markets. Each transaction is negotiated separately and the actual transaction price may be significantly different than the average of all transactions displayed as VWAP.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.